Related Experiment Video
Updated: May 16, 2026
05:42
The Forced Swim Test as a Model of Depressive-like Behavior
Published on: March 2, 2015
ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression
A B Singh1, C A Bousman, C H Ng
1School of Medicine, Deakin University, Geelong, VIC, Australia. a.singh@deakin.edu.au
Translational Psychiatry
|November 29, 2012
Summary
Genetic variations in the ABCB1 transporter influence antidepressant response. Specific ABCB1 gene variants (SNPs) can predict the required escitalopram or venlafaxine dose for remission in major depressive disorder patients.
Area of Science:
- Pharmacogenomics
- Neuroscience
- Molecular Biology
Background:
- The ATP-binding cassette subfamily B member 1 (ABCB1) transporter, also known as P-glycoprotein, is crucial for the blood-brain barrier.
- Many antidepressants are substrates for ABCB1 efflux, impacting their central nervous system bioavailability.
- Functional polymorphisms in ABCB1 may contribute to inter-individual variability in antidepressant treatment response.
Purpose of the Study:
- To investigate the association between ABCB1 single-nucleotide polymorphisms (SNPs), specifically rs1045642, and the required dose of escitalopram or venlafaxine for remission in major depressive disorder (MDD).
- To determine if ABCB1 genotype can predict antidepressant treatment outcomes.
Main Methods:
- Genotyping of ABCB1 SNPs (rs1045642, rs2032582, rs1128503) in 113 individuals with MDD.
- Treatment with escitalopram or venlafaxine for 8 weeks, with depression severity assessed using the Hamilton Depression Rating Scale.
- Statistical analysis controlling for demographic factors, clinical features, P450 metabolizer status, and 5-HTTLPR genotype.
Main Results:
- Patients with the rs1045642 TT genotype required significantly lower doses of escitalopram for remission compared to TC and CC carriers.
- A 2.0-fold greater escitalopram dose was needed for C carriers versus TT carriers at rs1045642.
- For venlafaxine, individuals with the TT genotype at rs1045642 had a higher remission rate (73.3%) compared to CC genotype (12.5%).
Conclusions:
- ABCB1 SNP rs1045642 genotype can predict the antidepressant dose needed for remission in MDD patients.
- These findings have potential clinical implications for personalized antidepressant dose selection and improving remission rates.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...